1'-(4-chlorobenzoyl)-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-5-carboxylic acid

ID: ALA5203174

Chembl Id: CHEMBL5203174

PubChem CID: 163399327

Max Phase: Preclinical

Molecular Formula: C20H17ClN2O4

Molecular Weight: 384.82

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)c1ccc2c(c1)C1(CCN(C(=O)c3ccc(Cl)cc3)CC1)C(=O)N2

Standard InChI:  InChI=1S/C20H17ClN2O4/c21-14-4-1-12(2-5-14)17(24)23-9-7-20(8-10-23)15-11-13(18(25)26)3-6-16(15)22-19(20)27/h1-6,11H,7-10H2,(H,22,27)(H,25,26)

Standard InChI Key:  NBNDZHLPEOMAMK-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5203174

    ---

Associated Targets(Human)

IP6K1 Tbio Inositol hexakisphosphate kinase 1 (80 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IP6K2 Tbio Inositol hexakisphosphate kinase 2 (79 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IP6K3 Tbio Inositol hexakisphosphate kinase 3 (42 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 384.82Molecular Weight (Monoisotopic): 384.0877AlogP: 3.16#Rotatable Bonds: 2
Polar Surface Area: 86.71Molecular Species: ACIDHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 4.12CX Basic pKa: CX LogP: 2.76CX LogD: -0.33
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.83Np Likeness Score: -0.66

References

1. Zhou Y, Mukherjee S, Huang D, Chakraborty M, Gu C, Zong G, Stashko MA, Pearce KH, Shears SB, Chakraborty A, Wang H, Wang X..  (2022)  Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions.,  65  (9.0): [PMID:35467861] [10.1021/acs.jmedchem.2c00220]

Source